169262 ⎘
Investigating or analysing materials by specific methods not covered by groups -; Biological material, e.g. blood, urine ; Haemocytometers; Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing; Immunoassay; Biospecific binding assay; Materials therefor for cancer; Specifically defined cancers of lung
LUNG CANCER DIAGNOSTICS AND THERAPEUTICS WITH MIR-660
#302Antibody binding to carbonic anhydrase and use thereof
#303Nidogen-1 Fragments Assay
#304ANTI-PD-L1 AND ANTI-CTLA-4 ANTIBODIES FOR TREATING NON-SMALL CELL LUNG CANCER
#305METHOD FOR PROVIDING TUMOUR-SPECIFIC T CELLS
#306DLL3 MODULATORS AND METHODS OF USE
#307Methods relating to lung cancer
#308Capture, identification and use of a new biomarker of solid tumors in body fluids
#309EphA5-binding antibodies and uses thereof and selection of phage-displayed accessible recombinant targeted antibodies
#310Methods of treating cancer
#311METHODS FOR TREATING CANCER
#312Peptides and combination of peptides for use in immunotherapy against small cell lung cancer and other cancers
#313Compositions and methods for predicting response to NaPi2b-targeted therapy
#314Cytokine profiling analysis
#315METHOD FOR DETECTING AND ISOLATING INVASIVE CANCER STEM CELLS EMPLOYING CELL-SURFACE AMFR AND THE USE THEREOF
#316Methods of diagnosing and prognosing lung cancer
#317ROS kinase in lung cancer
#318Compositions for detecting mutant anaplastic lymphoma kinase in lung cancer
#319Method for the diagnosis, prognosis and treatment of lung cancer metastasis
#320Peptides and combination of peptides for use in immunotherapy against small cell lung cancer and other cancers
#321Peptides and combination of peptides for use in immunotherapy against small cell lung cancer and other cancers
#322Protein and autoantibody biomarkers for the diagnosis and treatment of lung cancer
#323Angiogenesis Biomarkers Associated With Disease Progression in Lung Cancer
#324Anti-Ly6E antibodies and methods of use
#325PHARMECEUTICAL COMPOSITION FOR LUNG CANCER TREATMENT AND METHODS FOR PROVIDING INFORMATION AND SCREENING
#326Lysosomal acid lipase and PPAR gamma ligands as immune therapies for cancer treatment
#327Methods of Identification and Diagnosis of Lung Diseases Using Classification Systems and Kits Thereof
#328Antibody binding to HEG1 and use of the antibody for detection and treatment of mesothelioma
#329Lung cancer signature
#330ORGAN SPECIFIC DIAGNOSTIC PANELS AND METHODS FOR IDENTIFICATION OF ORGAN SPECIFIC PANEL PROTEINS
#331TREATMENT OF SMALL CELL LUNG CANCER WITH A PARP INHIBITOR
#332USE OF IL-1beta BINDING ANTIBODIES
#333DLL3 MODULATORS AND METHODS OF USE
#334Use of statin-based drug for treatment of EML4-ALK-positive non-small cell lung cancer progressing on ALK inhibitor
#335Methods and kits for the diagnosis of cancer
#336NOVEL SEZ6 MODULATORS AND METHODS OF USE
#337PLASMA AUTOANTIBODY BIOMARKERS FOR DIAGNOSIS OF LUNG CANCER
#338METHODS FOR TREATMENT AND SELECTION OF PATIENTS RESPONSIVE TO IMMUNE MEDIATED CANCER THERAPY
#339Compound for inhibiting binding between DX2 protein and p14/ARF protein, and pharmaceutical composition for treating or preventing cancer disease containing same as effective ingredient
#340Methods of identification, assessment, prevention and therapy of lung diseases and kits thereof including gender-based disease identification, assessment, prevention and therapy
#341System and method for isolating and analyzing cells
#342BUFADIENOLIDE FOR TREATMENT OF NON-SMALL CELL LUNG CANCER
#343METHODS AND MATERIALS FOR TREATING CANCER
#344System for isolating and analyzing cells in a single-cell format
#345DIAGNOSTIC BIOMARKER AND DIAGNOSTIC METHOD
#346Cancer treatment composition combining anti-CD26 antibody and other anticancer agent
#347Kinin-based theranostic probes for solid cancers and uses thereof
#348Monitoring Dysregulated Serum Complement, Coagulation, and Acute-Phase Inflammation Sub-Proteomes Associated with Cancer
#349Use of a Fibrinogen Capture Agent to Detect a Ciz1 B-Variant
#350Diagnosis of a neuroautoimmune disease
#351POLYPEPTIDES AND POLYNUCLEOTIDES, AND USES THEREOF AS A DRUG TARGET FOR PRODUCING DRUGS AND BIOLOGICS
#352METHODS OF DETECTING A RELAPSE OF A LUNG ADENOCARCINOMA BASED ON MARKER HUMAN EPIDIDYMIS PROTEIN 4 (HE4) AND RELATED USES
#353Lung cancer biomarkers and uses thereof
#354Short non-coding protein regulatory RNAs (sprRNAs) and methods of use
#355PHAGE MICROARRAY PROFILING OF THE HUMORAL RESPONSE TO DISEASE
#356Lymph node specimen collection kit
#357IGF2BP3 functional alterations and overexpression as a marker for cancer diagnosis and therapeutic response to IGF1R inhibitors
#358Methods for predicting the survival time of patients suffering from a lung cancer
#359Biomarkers in Peripheral Blood Mononuclear Cells for Diagnosing or Detecting Lung Cancers
#360COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF TUMOR
#361IDENTIFICATION OF PROTEIN ASSOCIATED WITH HEPATOCELLULAR CARCINOMA, GLIOBASTOMA AND LUNG CANCER
#362Methods of identifying an individual to be treated by chemotherapy based on cytokeratin-19 fragments (CYFRA 21-1) and carcinoembryonic antigen (CEA) marker molecules and related uses
#363Using phage epitopes to profile the immune response
#364IDENTIFICATION OF PREDICTIVE BIOMARKERS ASSOCIATED WITH WNT PATHWAY INHIBITORS
#365Anti-GPNMB antibodies and diagnostic uses thereof
#366Methods relating to lung cancer
#367THERAPEUTIC AND DIAGNOSTIC TARGET FOR CANCER COMPRISING DLL3 BINDING REAGENTS
#368Anti-human TIM-3 antibodies and methods of use thereof
#369Method of detecting lung cancer
#370Methods of treating lung cancer by predicting responders to cisplatin-pemetrexed combination therapy
#371USE OF CYP EXPRESSION TO DIRECT THERAPEUTIC INTERVENTION IN CANCER
#372BIN1 expression as a marker of cancer
#373Methods of determining interferon having direct inhibitory effects on tumors and uses thereof
#374Use of circulating tumor cell mitotic index in cancer stratification and diagnostics
#375TREATMENT OF PD-L1 POSITIVE LUNG CANCER USING AN ANTI-PD-1 ANTIBODY
#376Method of determining a protein in a sample
#377Methods of detecting per cell PD-L1 expression and uses thereof
#378Conjugated porphyrin carbon quantum dots for targeted photodynamic therapy
#379METHODS FOR TREATING LUNG CANCER
#380NOVEL RISK BIOMARKERS FOR LUNG CANCER
#381Method of predicting effect of treatment by PD-1/PD-L1 blockade using abnormality of PD-L1 (CD274) as index
#382Method and kit for use in inhiiting tumor progression, predicting or determining tumor progression state in VGF expressing cancers
#383STANDARD CELL SUSPENSION
#384System and method for isolating and analyzing cells
#385Lung cancer diagnosis marker, antibody and application thereof
#386Compositions and Methods for Diagnosing and Treating Cancer
#387METHOD OF IDENTIFYING PROTEINS IN HUMAN SERUM INDICATIVE OF PATHOLOGIES OF HUMAN LUNG TISSUES
#388Immunohistochemical assay for detecting expression of programmed death ligand 1 (PD-L1) in tumor tissue
#389Methods of determining an immune response score
#390LUNG CANCER BIOMARKERS
#391Risk Factors of Cigarette Smoke-Induced Spriometric Phenotypes
#392EXOSOME-CONJUGATED QUANTUM DOT NANOPARTICLES AND METHODS OF DETECTING EXOSOMES AND CANCER USING SAME
#393Compositions, methods and kits for diagnosis of lung cancer
#394Method for using information on complex biomarker group to diagnose lung cancer in a subject and diagnostic kit and computing system using the same
#395METHOD FOR TREATING CANCER
#396Compositions, methods and kits for diagnosis of lung cancer
#397EMBRYONIC ISOFORMS OF GATA6 AND NKX2-1 FOR USE IN LUNG CANCER DIAGNOSIS
#398Modulation of cancer immunity with type 2 innate lymphoid cells, interleukin 33, and/or interferon induced protein 44
#399METASTATIC CANCER DECOY TRAP
#400MOLECULAR PROFILING FOR CANCER
#401CKAP4-molecular-targeted antitumor agent
#402Methods of delivering DLL3 antibody drug conjugates
#403Methods of making DLL3 antibody drug conjugates
#404MULTIPLEX ASSAY FOR IMPROVED SCORING OF TUMOR TISSUES STAINED FOR PD-L1
#405THERAPEUTIC AND DIAGNOSTIC METHODS FOR CANCER
#406EVALUATING METHOD, EVALUATING APPARATUS, EVALUATING PROGRAM PRODUCT, EVALUATING SYSTEM, AND TERMINAL APPARATUS
#407Use of isocitrate dehydrogenase 1 as a diagnostic and prognostic biomarker and therapeutic target for lung cancers
#408Anti-DLL3 antibody drug conjugates and methods of use
#409Compositions, methods and kits for diagnosis of lung cancer
#410METHODS AND KITS FOR ANALYSIS OF HMGB1 ISOFORMS
#411Anti-DLL3 antibody drug conjugates
#412IMMUNE MODULATORS IN COMBINATION WITH RADIATION TREATMENT
#413Use of ubiquitin-proteasome system inhibitors for treatment of tumors associated with neurofibromatosis type-2
#414MULTIPLEXED IMMUNOHISTOCHEMISTRY ASSAYS FOR DIAGNOSIS AND TREATMENT OF CANCER
#415METHODS AND COMPOSITIONS FOR TREATING AND DIAGNOSING DISEASES
#416Histochemical assay for evaluating expression of programmed death ligand 1 (PD-L1)
#417Methods and compositions for single chain variable region ENOX2 antibodies for cancer detection and diagnosis
#418DIAGNOSTIC AND PROGNOSTIC METHODS FOR LUNG DISORDERS USING GENE EXPRESSION PROFILES FROM NOSE EPITHELIAL CELLS
#419Sialyltransferase ST3GAL6 as a marker for multiple myeloma
#420Anti-MFI2 antibodies and methods of use
#421METHOD FOR SCREENING COMPOUND SPECIFICALLY SUPPRESSING FORMATION OF CAVEOLAE OF CANCER CELLS, SCREENING KIT, VECTOR AND TRANSFORMANT TO BE USED IN KIT, AND METHOD FOR SELECTING PATIENT FOR WHOM MOLECULARLY TARGETED DRUG IS INDICATED
#422Method for treating epstein-barr virus—positive cancer with immunotherapy
#423Kits containing DLL3 antibody drug conjugates
#424METHOD FOR PREDICTING THE RISK OF GETTING CANCER OR DIAGNOSING CANCER IN A FEMALE SUBJECT
#425Salivary Biomarkers for Lung Cancer Detection
#426MTOR kinase mutations and methods of use thereof
#427Methods of evaluating patients using E-cadherin or vimentin
#428Molecular diagnosis and typing of lung cancer variants
#429RSPO BINDING AGENTS AND USES THEREOF
#430Methods and materials for identifying and treating mammals having lung adenocarcinoma characterized by neuroendocrine differentiation
#431Early lung cancer detection by DNA methylation phenotyping of sputum-derived cells
#432Lung cancer differential marker
#433METHODS FOR IDENTIFYING PATIENTS RESPONSIVE TO ANTI-PD-L1 ANTIBODY THERAPY
#434Anti-DLL3 antibody drug conjugates
#435COMPOSITIONS, METHODS AND KITS FOR DIAGNOSIS OF LUNG CANCER
#436Use of EI24 gene
#437Saccharide-based biomarkers and therapeutics
#438Anti-DLL3 antibody drug conjugates for treating cancer
#439Methods of making DLL3 antibody drug conjugates
#440Methods of delivering DLL3 antibody drug conjugates
#441Anti-DLL3 antibody drug conjugates
#442Protein and autoantibody biomarkers for the diagnosis and treatment of lung cancer
#443CARCINOMA HOMING PEPTIDE (CHP), ITS ANALOGS, AND METHODS OF USING
#444LOX and LOXL2 inhibitors and uses thereof
#445Method of identifying anti-VISTA antibodies
#446PRKC fusions
#447Method of identifying treatment responsive non-small cell lung cancer using anaplastic lymphoma kinase (ALK) as a marker
#448BARD1 isoforms in lung and colorectal cancer and use thereof
#449CARBON NANOTUBE ORGANIC SEMICONDUCTOR, MANUFACTURING METHOD THEREOF, AND TRANSISTOR FOR CHEMICAL SENSOR USING THE SAME
#450Methods and Compositions for Modulating Lung Cancer Tumor Initiating Cells (TIC), and Oxytocin Receptor (OXTR) Modulatory Agents for Use in Practicing the Same
#451Lung cancer adjuvant therapy
#452Non-Invasive Gene Mutation Detection in Lung Cancer Patients
#453Organ Specific Diagnostic Panels and Methods for Identification of Organ Specific Panel Proteins
#454Antibody to mucin 4 (MUC4) glycopeptide and uses thereof
#455Method and kits for identifying of CDK9 inhibitors for the treatment of cancer
#456Anti-folate receptor alpha antibodies and uses thereof
#457COMPOSITIONS, METHODS AND KITS FOR DIAGNOSIS OF LUNG CANCER
#458SRM ASSAYS TO CHEMOTHERAPY TARGETS
#459PROTEIN BIOMARKER AND USES THEREOF
#460LUNG CANCER BIOMARKERS
#461System and method for isolating and analyzing cells
#462Lung cancer markers and uses thereof
#463Diagnosis and treatment of cancer using anti-desmoglein-3 antibodies
#464Tumor suppressor and oncogene biomarkers predictive of anti-immune checkpoint inhibitor response
#465Compound for inhibiting binding between DX2 protein and P14/ARF protein, and pharmaceutical composition for treating or preventing cancer disease containing same as effective ingredient
#466ANTIBODIES AND METHODS OF USING SAME FOR TREATING ErbB/ErbB LIGANDS ASSOCIATED DISEASES
#467Method for detection of a TECR:PKN1 or an ANXA4:PKN1 gene fusion
#468SLIT-ROBO-Myo9-RHOA PATHWAY AND CANCER
#469Provasopressin antagonists and uses thereof
#470Peptides and combination of peptides for use in immunotherapy against small cell lung cancer and other cancers
#471Immunoassay method for pro-gastrin-releasing peptide
#472Composition and Method for Diagnosis and Immunotherapy of Lung Cancer
#473Method for differentiating between lung squamous cell carcinoma and lung adenocarcinoma
#474Compositions and methods for the diagnosis and treatment of tumor
#475Anti-B7-H3 antibodies and diagnostic uses thereof
#476Method of treating cancer using a caspase-4 inhibitor
#477Method of determining a protein in a sample
#478Pleural fluid markers for malignant pleural effusions
#479Anti-Ly6E antibodies and methods of use
#480INTERTUMORAL HOMOGENEITY DETERMINED BY MICK ASSAY
#481HSF1 IN TUMOR STROMA
#482Methods and compositions for single chain variable region ENOX2 antibodies for cancer detection and diagnosis
#483Methods for single chain variable region ENOX2 antibodies for cancer detection and diagnosis
#484Diagnosis of cancer by detecting dimeric IL-18
#485Methods for analyzing rare circulating cells
#486EGFR/NEDD9/TGF-β interactome and methods of use thereof for the identification of agents having efficacy in the treatment of hyperproliferative disorders
#487Anti-DLL3 antibody drug conjugates for treating cancer
#488ARMET AS A MARKER FOR CANCER
#489Antigen associated with lung cancers and lymphomas
#490Methods for treating cancer by inhibiting FGFR3/TACC3 fusion protein
#491NOVEL LUNG CANCER BIOMARKER (LIPH)
#492Magnetic Nanoparticle Conjugate and Use Thereof
#493LKB1 related diagnostics and treatments of cancer
#494METHODS OF GRADING CARCINOMAS
#495Blockade of CCL18 signaling via CCR6 as a therapeutic option in treating interstitial lung disease
#496Method for Detecting Lung Cancer
#497Angiogenesis Biomarkers Associated with Disease Progression in Lung Cancer
#498Methods of treating non-small cell lung carcinoma (NSCLC)
#499Anti-p40 antibodies systems and methods
#500HEPATOCYTE GROWTH FACTOR AS MARKER OF PROGNOSIS IN SMALL CELL LUNG CANCER (SCLC)
#501SRM/MRM assay for subtyping lung histology
#502Methods And Marker Combinations For Screening For Predisposition To Lung Cancer
#503Biomarkers of rapid progression in advanced non-small cell lung cancer
#504High temperature selection of nucleotide-supported carbohydrate vaccines and resulting glycosylated oligonucleotides
#505Kynurenine Pathway Biomarkers Predictive of Anti-Immune Checkpoint Inhibitor Response
#506SEZ6 modulators and methods of use
#507CANCER URINE TEST
#508METHOD FOR DIAGNOSING LUNG CANCERS USING GENE EXPRESSION PROFILES IN PERIPHERAL BLOOD MONONUCLEAR CELLS
#509Lung cancer diagnosis
#510NOVEL METHOD TO DETECT RESISTANCE TO CHEMOTHERAPY IN PATIENTS WITH LUNG CANCER
#511METHODS FOR DIAGNOSING CANCER AND DETERMINING THE OVERALL SURVIVAL AND DISEASE-FREE SURVIVAL OF CANCER PATIENTS
#512Antibody specific to the AIMP2-DX2
#513Phage microarray profiling of the humoral response to disease
#514Isoforms of GATA6 and NKX2-1 as markers for diagnosis and therapy of cancer and as targets for anti-cancer therapy
#515Diagnostic methods for determining prognosis of non-small cell lung cancer
#516Markers for the epithelial and proliferative or mesenchymal invasive phenotype of human neoplasia
#517MOLECULAR PROFILING OF TUMORS
#518Methods and systems for determining proportions of distinct cell subsets
#519INHIBITING CANCER METASTASIS
#520Monoclonal antibodies to human 14-3-3 epsilon and human 14-3-3 epsilon sv
#521Identification of Non-Small Cell Lung Carcinoma (NSCLC) Tumors Expressing PDGFR-alpha
#522Compositions for detecting mutant anaplastic lymphoma kinase in lung cancer
#523Methods of treating cancer by administering a soluble receptor comprising a human Fc domain and the Fri domain from human frizzled receptor
#524MPS peptides and use thereof
#525PROTEIN
#526Compositions, methods and kits for diagnosis of lung cancer
#527Method for the diagnosis and prognosis of cancer
#528Methods and compositions for treating and diagnosing diseases
#529Compositions, Methods and Kits for Diagnosis of Lung Cancer
#530Anti-human CD26 monoclonal antibody or antigen-binding fragment thereof
#531Aptamers and use of the aptamers in the diagnosis and treatment of cancer
#532Method for the prognosis of survival time of a patient suffering from a solid cancer
#533DETECTING CANCER WITH ANTI-CXCL16 AND ANTI-CXCR6 ANTIBODIES
#534SYSTEMS AND METHODS FOR DIAGNOSING AND TREATING CANCER
#535Blood markers for diagnosing epithelium derived cancers and monoclonal antibodies thereof
#536Lung cancer diagnostic method and means
#537Lung cancer biomarker
#538LUNG CANCER DIAGNOSTICS AND THERAPEUTICS WITH MIR-660
#539ANTI-MEASLES CANCER IMMUNOTHERAPY
#540Identification of protein associated with hepatocellular carcinoma, gliobastoma and lung cancer
#541Compositions and methods for diagnosing lung cancers
#542Anti-DLL3 antibodies
#543COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND PROGNOSIS OF LUNG CANCER
#544Mathematical musical orchestral method for predicting classes of patients for medical treatment
#545SRM/MRM assay for subtyping lung histology
#546Compositions, methods and kits for diagnosis of lung cancer
#547Using phage epitopes to profile the immune response
#548Fully human antibodies to high molecular weight-melanoma associated antigen and uses thereof
#549Drug selection for non-small cell lung cancer therapy
#550Cytotoxic T lymphocyte inducing immunogens for prevention treatment and diagnosis of cancer
#551METHODS AND MATERIALS FOR IDENTIFYING AND TREATING MAMMALS HAVING LUNG ADENOCARCINOMA CHARACTERIZED BY NEUROENDOCRINE DIFFERENTIATION
#552Gene signature to predict homologous recombination (HR) deficient cancer
#553Therapeutic and diagnostic methods relating to cancer stem cells
#554Anti-RSPO2 antibodies and uses thereof
#555Targeting phosphofructokinase and its glycosylation form for cancer
#556Method of Treating Patients with a Mucinous Glycoprotein (MUC-1) Vaccine
#557Method for predicting the risk of getting cancer or diagnosing cancer in a subject
#558Method of identifying treatment responsive non-small cell lung cancer using anaplastic lymphoma kinase (ALK) as a marker
#559METHOD FOR OBTAINING DATA THAT ARE USEFUL FOR THE DIAGNOSIS, PROGNOSIS AND CLASSIFICATION OF PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) AND/OR LUNG CANCER
#560COMPOSITION FOR DIAGNOSIS OF LUNG CANCER AND DIAGNOSIS KIT FOR LUNG CANCER
#561Anti-DLL3 antibody drug conjugates
#562BLOOD MARKERS FOR LUNG CANCER PREDISPOSITION
#563Systems and methods for diagnosing and treating cancer
#564Antibody cocktail systems and methods for classification of histologic subtypes in lung cancer
#565FGFR3 fusion gene and pharmaceutical drug targeting same
#566Biological materials related to c-Met
#567Fully human antibodies and fragments recognizing human c-Met
#568METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER
#569Method for detecting lung squamous cell carcinoma
#570Methods of evaluating patients using E-cadherin and vimentin
#571RET inhibitor
#572Method for predicting the risk of getting cancer or diagnosing cancer in a female subject
#573Biomarkers in peripheral blood mononuclear cells for diagnosing or detecting lung cancers
#574Methods for the identification, assessment, and treatment of patients with cancer therapy
#575Use of isocitrate dehydrogenase 1 as a diagnostic and prognostic biomarker and therapeutic target for lung cancers
#576NOVEL METHOD TO DETECT RESISTANCE TO CHEMOTHERAPY IN PATIENTS WITH LUNG CANCER
#577Integrated quantification method for protein measurements in clinical proteomics
#578METHOD OF DETERMINING A PROTEIN IN A SAMPLE
#579Lung cancer specific peptides for targeted drug delivery and molecular imaging
#580Method for predicting efficacy of c-Met inhibitor
#581CANCER CLASSIFICATION AND METHODS OF USE
#582Methods And Marker Combinations For Screening For Predisposition To Lung Cancer
#583Histological markers for identifying non-small cell lung carcinoma patients for treatment with an anti-EGFR drug
#584LUNG CANCER DIAGNOSTIC ASSAY
#585LUNG CANCER SIGNATURE
#586Method for the diagnosis, prognosis and treatment of lung cancer metastasis
#587METHODS AND PRODUCTS RELATED TO LUNG CANCER
#588High-affinity monoclonal antibodies to glypican-3 and use thereof
#589PROTEIN BIOMARKER AND USES THEREOF
#590IL-17 HOMOLOGOUS POLYPEPTIDES AND THERAPEUTIC USES THEREOF
#591MULTIPLEXED ASSAY METHOD FOR LUNG CANCER CLASSIFICATION
#592Immune biomarkers and assays predictive of clinical response to immunotherapy for cancer
#593METHOD FOR CHARACTERIZING CIRCULATING TUMOR CELLS, AND USE THEREOF IN DIAGNOSIS
#594Anti-Ly6E antibodies and methods of use
#595METHOD OF IDENTIFYING PROTEINS IN HUMAN SERUM INDICATIVE OF PATHOLOGIES OF HUMAN LUNG TISSUES
#596Method for identification, selection and analysis of tumour cells
#597Method for the diagnosis or prognosis, in vitro, of lung cancer
#598METHODS FOR THE TREATMENT, THE PROGNOSTIC ASSESSMENT AND THE STAGING OF NON-SMALL CELL LUNG CANCER
#599METHOD FOR PEPTIDE HISTOCHEMICAL DIAGNOSIS
#600Method for the Selection of Serum Biomarkers of Epigenetic Alterations, Particularly of Global Hypomethylation and Their Uses